Bukwang teams up with LSK Biopartners over investigational anticanger drug

Published: 2009-01-13 06:55:00

Updated: 2009-01-13 06:55:00

Bukwang Pharm has acquired the exclusive license from the US based LSK Biopartners to develop, manufacture and market the compound YN968D1 in Korea, it was announced on January 8.

This compound s a potent, orally administered small-molecule angiogenesis inhibitor with the potential to fight so...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK